- Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study
-
Li J, Kang J, Wang C, Yang J, Wang L, Kottakis I, Humphries , Zhong N, China Omalizumab Study Group
- KMID: 2165915
- Allergy Asthma Immunol Res.
- 2016 Jul;8(4):319-328.
- doi: 10.4168/aair.2016.8.4.319
PURPOSE: Omalizumab is the preferred add-on therapy for patients with moderate-to-severe persistent allergic asthma and has demonstrated efficacy and safety in various ethnicities. This study evaluated the efficacy and safety... -
- CITED
-
- Close
- SHARE
-
- Close
